Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen
暂无分享,去创建一个
S. Sleijfer | J. Foekens | M. Look | E. Berns | P. Span | S. Linn | F. Sweep | L. Dirix | S. V. van Laere | M. Jansen | I. Lurkin | Diana E. Ramirez-Ardila | K. Ruigrok-Ritstier | J. C. Helmijr | J. Helmijr